Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07065721

Continuous Glucose Monitoring for Self-Management of Type 2 Diabetes in Young Adults

Type 2 diabetes in increasing common in young adults. Utilizing a mixed-methods, community-based approach, this study offers continuous glucose monitors (CGMs) to young adults with type 2 diabetes for 30 days, and collects both quantitative and qualitative data to understand barriers and facilitators of CGM use, participants' changes in awareness of glucose patterns while using the CGM, and preferences for a CGM-based self-management intervention.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Scripps Health

San Diego, California, 92121, United States

Location status: Recruiting

Location contact

Samantha Bagsic, PhD

CONTACT

[email protected]

858-554-5708

About this study

The prevalence of type 2 diabetes (T2D) is rising in young adults and is associated with increased complications and reduced life expectancy. Poor adherence to diabetes self-management behaviors is common in young adulthood, often leading to poor glycemic control, and existing self-management interventions have had limited effectiveness in this age group. Continuous glucose monitors (CGMs) provide real-time glucose data that can support behavior change and reduce common self-management barriers such as glycemic unawareness, but their use in younger adults is limited. As "digital natives," young adults are well-poised to benefit from CGM interventions, particularly if they reduce barriers of standard self-management education (e.g., time burden). Qualitative data has shown that young adults are interested in CGM use but lack both access to CGMs and understanding of how to best utilize CGM data. The purpose of this proposal is to utilize a mixed-methods, community-engaged approach to generate pilot data for the development of a self-management intervention that pairs CGM glucose data with behavioral data (e.g., FitBit step count, dietary intake) to improve self-management and glycemic awareness and control. Young adults with T2D will be recruited to participate in a 30-day trial wear of CGMs, during which self-management behaviors will also be assessed. Afterward, qualitative interviews with participants will be conducted to understand barriers and facilitators of CGM use, changes in awareness of glucose patterns, and preferences for a CGM-based intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult 18-45 years of age
  • diagnosis of type 2 diabetes in the last 5 years, as evidenced in the electronic medical record
  • no prior use or experience with wearable CGMs
  • possession of a smart phone that is compatible with Dexcom CGM sensors (nearly all smartphones are compatible) and willing to download and utilize the Dexcom CGM app
  • fluency in English or Spanish

Exclusion criteria

  • severe mental illness (e.g., psychosis, suicidal ideation);
  • pregnancy or <6 months postpartum

Treatment and study plan

Continuous Glucose Monitor

Device

Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.

Primary outcomes

  1. Qualitative data regarding CGM use

    Time frame: Immediately after the intervention

    Semi-structured qualitative interviews will be conducted to understand barriers and facilitators of CGM use, changes in awareness of glucose patterns or relationships between glucose and health behaviors, and preferences for a future CGM-based intervention.

Secondary outcomes

  1. Acceptability and feasibility of CGM wear

    Time frame: Immediately after the intervention

    Mean rating of CGM feasibility, acceptability, utility, satisfaction ≥ 3/5 on a 0-5 scale

Other outcomes

  1. Glucose time-in-range

    Time frame: 30 days (during the intervention period)

    Percent of time that glucose readings are in target range (70-180 mg/dL)

  2. Diabetes self-care behaviors

    Time frame: One week (7 days), last week of the intervention

    Self-report of diabetes self-management behaviors (e.g., healthy eating, physical activity) in the last 7 days using the 13-item Summary of Diabetes Self-care Behaviors Scale (range 0-91, higher = more frequent self-management behaviors).

  3. Diabetes distress

    Time frame: Baseline and follow-up (immediately after the intervention)

    Diabetes distress measured using the Problem Areas in Diabetes scale; range 0-80; higher score = higher diabetes distress

  4. Self-management motivation

    Time frame: Baseline and follow-up (immediately after the intervention)

    Motivation and attitudes about behavioral diabetes self-management utilizing the 9-item Motivation and Attitudes Toward Changing Health measure (range: 9-45, higher scores = greater motivation/more positive attitude).

  5. Self-reported physical activity

    Time frame: Baseline and follow-up (immediately after the intervention)

    Self-reported moderate and vigorous physical activity using the International Physical Activity Questionnaire (scored as metabolic equivalent units per week)

  6. Objectively measured physical activity

    Time frame: 30 days (during the intervention period)

    FitBit-sensed step count (weekly average)

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica L McCurley, PhD, MPH

CONTACT

[email protected]

619-594-2132

Sponsors and collaborators

Lead sponsor

San Diego State University

Other

Collaborators

  • Scripps Health

Registry information

Official study title

CAPAZ-2D: Continuous Glucose Monitoring to Augment and Personalize Self-Management of Type 2 Diabetes in Hispanic/Latinx Young Adults

Acronym: CAPAZ-2D

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 15, 2025
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.